Acurate neo2™ aortic valve system data presented at late-breaking clinical trial session at tct 2024

Marlborough, mass. and washington , oct. 30, 2024 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced the results of the primary endpoint of the acurate ide clinical trial, which evaluated the acurate neo2™ aortic valve system in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery.
BSX Ratings Summary
BSX Quant Ranking